Back to results
US 12,721,914 B2Granted
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMarcus Kelly, Dangshe Ma, William Olson, Gavin Thurston, Richard Tavare
Life of this patent
Estimating the term…
Abstract
Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.
Claims16
A method for identifying a candidate for anti-tumor therapy, the method comprising:
- (i) administering a radiolabeled anti-LAG3 antibody conjugate to a patient with a solid tumor, wherein the radiolabeled anti-LAG3 antibody conjugate comprises an anti-LAG3 antibody or antigen-binding fragment thereof comprising:
- three heavy chain complementarity determining regions (HCDRs) in a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 2, 18, 34, 50, 66, 82, 98, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 322, 338, 354, 370, 386, 402, 418, 434, 458, 466, 474, 482, 490, 498, 506, 514, 538, and 554;
- and three light chain complementarity determining regions (LCDRs) in a light chain variable region (LCVR), wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, 378, 394, 410, 426, 442, 522, 530, 546, and 562;
- (ii) visualizing LAG3 expression by positron emission tomography (PET) imaging,
- wherein presence of the radiolabeled antibody conjugate in the tumor identifies the patient as a candidate for anti-tumor therapy.
4 more elements
Dependencies are inferred from the claim text.